US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE® Smallpox Vaccine



Kvistgaard, Denmark, November 17 2009 - Bavarian Nordic A/S (OMX:
BAVA) announced today that BARDA (Biomedical Advanced Research and
Development Authority) has awarded a new contract to Bavarian Nordic
for the development of a freeze-dried version of its IMVAMUNE®
smallpox vaccine with a total prospective value of USD 40 million.

The contract provides funds to validate the new freeze-dried
manufacturing process and the associated pre-clinical and clinical
studies to support the advanced development of a freeze-dried version
of IMVAMUNE®. The base year funding represents 33% of the total
contract value, followed by four additional years of optional
funding, which are triggered by the completion of pre-determined
technical milestones. These freeze-dried development activities will
be performed in parallel to the licensure activities of the current
liquid-frozen IMVAMUNE® formulation under the RFP-3 contract.

The contract does not affect the company's expectations for the 2009
full year results.

With this contract, the US Government has to-date awarded contracts
to Bavarian Nordic for the development and procurement of IMVAMUNE®
worth more than USD 680 million. Under the ongoing RFP-3 contract,
Bavarian Nordic will deliver 20 million doses of IMVAMUNE® in the
current liquid-frozen formulation. Once the contract option for an
additional 60 million doses is expectedly exercised, these vaccines
will be delivered in the liquid-frozen formulation as well. Thus, the
new contract will have no influence on the ongoing contracts, but
represents an additional business opportunity and will expectedly
constitute the gateway towards securing additional contracts for this
new freeze-dried version with the US Government and outside the US as
well.

A freeze-dried formulation of IMVAMUNE® offers various new advantages
in terms of a potential increased shelf-life compared to the current
liquid-frozen formulation. Additionally, this would help overcome the
challenges with the cold-chain logistics and storage.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are
excited about receiving yet another contract from the US Government
in support for the development of an advanced freeze-dried version of
our IMVAMUNE® smallpox vaccine. It clearly demonstrates the continued
commitment from the US Government to support the development of
advanced medical countermeasures and it strengthens our confidence,
that the option to procure up to an additional 60 million doses of
IMVAMUNE® under the ongoing RFP-3 contract will be exercised."



Asger Aamund
Chairman of the Board


Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

Attachments

2009-27-uk.pdf
GlobeNewswire